Strike Three As Novartis’s Ilaris Swings And Misses In Lung Cancer

Anti-Inflammatory Drug Fails In A Third Setting

 
• By Mandy Jackson
  
Target shot opportunity dartboard performance
The third Phase III miss for Ilaris in NSCLC is in the adjuvant setting • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D